Life Sciences Tools and Services
Company Overview of BioScale, Inc.
BioScale, Inc., a life science tool company, develops, manufactures, and promotes protein measurement tools to accelerate drug discovery, development, and production of biological and pharmaceutical products. The company offers acoustic membrane microparticle technology based ViBE protein analysis platform that allows design and configuration of protein assays for highly-sensitive detection and quantitation of proteins in biological samples used in pre-clinical and clinical research, bioprocessing, patient point-of-care, and personalized medicine applications. Its ViBE platform comprises ViBE BioAnalyzer, a research tool for assay development or small to medium size studies; and ViBE Worksta...
4 Maguire Road
Lexington, MA 02421
Founded in 2002
Key Executives for BioScale, Inc.
Vice President of Finance & Administration
Compensation as of Fiscal Year 2012.
BioScale, Inc. Key Developments
BioScale, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 09:30 AM
Dec 18 12
BioScale, Inc. Presents at EBD Group AG's Biotech showcase 2013, Jan-07-2013 09:30 AM. Venue: Parc 55 Wyndham Union Square Hotel, San Francisco, California, United States. Speakers: Mark Lundstrom, Co-Founder, Chief Executive Officer, President and Director.
BioScale, Inc. Presents Comparative Analysis of in Vitro and in Vivo Kinase Activity and Expression Using the AMMP(R) Assay at the European Association of Cancer Research Meeting
Jul 9 12
BioScale, Inc. presented findings of recently completed research studies on phospho-protein analysis of the in vitro and in vivo kinase expression in the MAP kinase pathway at the 22nd Biennial European Association for Cancer Research (EACR) Congress, held in Barcelona, Spain, July 7-10, 2012. The presentation entitled "Comparative Analysis of in vivo and in vitro Expression of Kinases in the MAPK Kinase Pathway" was presented by Lee Anne Beausang, Ph.D. Senior Assay Development Scientist. The studies reported here utilized non-optical, AMMP(R) (acoustic membrane microparticle) technology to assess and quantify the activation states of several implicated kinases: EGFR, p38, and AKT in their native state from multiple cancer cell lines. Phosphorylation states of kinases from multiple human tumor cell line lysates, with or without mitogenic stimulation, were compared with lysates prepared from xenografted tumors derived from the same cell lines. The results indicated successful measurement of native phospho- and total kinase biomarkers in xenografted tumors and the cell lines from which they were derived with nearly identical levels - a novel result that had not previously encountered in published literature. The relationship between total protein and cell numbers allows for an assessment of sensitivity based on cell numbers (<1000 cells/measurement). This is advantageous when analyzing tumor biopsy samples where cell numbers are generally low, and allows for more screening options with limited sample. The numbers of cells required for the determinations are consistent with those available from fine needle aspiration of in situ tumors, thus permitting the potential for "finger-printing" a specific tumor and evaluating multiple chemotherapeutic regimens against the tumor. These studies have also demonstrated the feasibility of quantifying biomarker analytes in the complex matrices of cell and tumor lysates with significant correlation between quantitated biomarker and the AMMP signal. The quantitation (mass/volume) of biomarker proteins using the AMMP assay format permits the elucidation of the phospho- to total kinase ratios observed in both tumor cell lines and xenografted tumors derived from them. These ratios appear to be characteristic of the individual cell lines, and will provide medicinal chemists additional criteria from which to define appropriate therapeutic targets for drug discovery.
BioScale, Inc. Appoints Martin Latterich as Chief Scientific Officer
Jun 12 12
BioScale, Inc. announced the appointment of Martin Latterich, PhD as chief scientific officer. Most recently Martin served as a Professor at the Proteogenomics Research Institute for Systems Medicine in San Diego. Dr. Latterich also held senior management positions at several biotechnology companies, including Diversa and Illumina.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|